EGFR and non-small cell lung carcinoma: To sum up, this study demonstrated that age, bone metastases and CA19-9 can be used to construct an ABC-Score to predict the efficacy of icotinib as an EGFR-TKI targeted therapy for advanced EGFR-positive NSCLC patients.